Blue Earth Diagnostics said that its Axumin (fluciclovine F-18) PET radiopharmaceutical has been added to the latest version of the National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer.
In version 1.2018 of the guidelines, the NCCN noted that either F-18 fluciclovine PET/CT or PET/MRI should be considered in the clinical workup of patients with recurrence or progression of their prostate cancer, according to Blue Earth. Axumin is indicated for use in PET imaging to identify suspected sites of prostate cancer recurrence in men who have elevated blood levels of prostate-specific antigen (PSA) after prior treatment.
